Hesperadin

Hesperadin is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin inhibits Aurora B with an IC50 of 250 nM. Hesperadin inhibits the growth of Trypanosoma brucei by blocking nuclear division and cytokinesis. Hesperadin also is a broad-spectrum influenza antiviral[1][2][3].

Product Specifications

CAS Number

[422513-13-1]

UNSPSC

12352005

Hazard Statement

H302

Target

Aurora Kinase; Autophagy; Influenza Virus; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Hesperadin.html

Purity

98.89

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C1NC2=CC=C(C=C2/C1=C(NC3=CC=C(C=C3)CN4CCCCC4)\C5=CC=CC=C5)NS(CC)(=O)=O

Molecular Formula

C29H32N4O3S

Molecular Weight

516.65

Precautions

H302

References & Citations

[1]Neal J, et, al. The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms. Mol Microbiol. 2009 Apr; 72 (2) : 442-58.|[2]Wahafu A, et, al. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide. Pathol Res Pract. 2019 Nov; 215 (11) : 152617.|[3]Hu Y, et, al. Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral. Int J Mol Sci. 2017 Sep 8;18 (9) :1929.